Compare Shionogi & Co., Ltd. with Similar Stocks
Dashboard
1
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 13.50%
- Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 55.35
2
Positive results in Mar 26
3
With ROE of 12.84%, it has a very attractive valuation with a 2.06 Price to Book Value
4
Majority shareholders : FIIs
Stock DNA
Pharmaceuticals & Biotechnology
JPY 2,548,796 Million (Large Cap)
16.00
NA
0.00%
-0.14
12.84%
1.68
Revenue and Profits:
Net Sales:
138,993 Million
(Quarterly Results - Mar 2026)
Net Profit:
47,702 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-16.48%
0%
-16.48%
6 Months
3.96%
0%
3.96%
1 Year
12.39%
0%
12.39%
2 Years
-53.2%
0%
-53.2%
3 Years
-54.68%
0%
-54.68%
4 Years
-58.56%
0%
-58.56%
5 Years
-50.47%
0%
-50.47%
Shionogi & Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.96%
EBIT Growth (5y)
9.00%
EBIT to Interest (avg)
55.35
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.27
Sales to Capital Employed (avg)
0.33
Tax Ratio
15.55%
Dividend Payout Ratio
30.61%
Pledged Shares
0
Institutional Holding
0.05%
ROCE (avg)
17.59%
ROE (avg)
13.50%
Valuation key factors
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
2.06
EV to EBIT
18.00
EV to EBITDA
15.89
EV to Capital Employed
2.23
EV to Sales
6.26
PEG Ratio
1.00
Dividend Yield
NA
ROCE (Latest)
12.41%
ROE (Latest)
12.84%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.05%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
138,993.00
147,719.00
-5.91%
Operating Profit (PBDIT) excl Other Income
38,504.00
62,751.00
-38.64%
Interest
2,838.00
1,611.00
76.16%
Exceptional Items
0.00
0.00
Consolidate Net Profit
47,702.00
74,680.00
-36.12%
Operating Profit Margin (Excl OI)
199.60%
383.90%
-18.43%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -5.91% vs 30.51% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -36.12% vs 69.02% in Dec 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
499,677.00
438,268.00
14.01%
Operating Profit (PBDIT) excl Other Income
188,348.00
180,712.00
4.23%
Interest
1,284.00
1,646.00
-21.99%
Exceptional Items
-37,382.00
-7,698.00
-385.61%
Consolidate Net Profit
205,914.00
169,534.00
21.46%
Operating Profit Margin (Excl OI)
323.00%
364.60%
-4.16%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 14.01% vs 0.73% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 21.46% vs 5.58% in Mar 2025
About Shionogi & Co., Ltd. 
Shionogi & Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






